Pasar al contenido principal

USO DE LETALIDAD SINTETICA EN GENES MODIFICADORES DE LA CROMATINA PARA EL TRATAMIENTO DE CANCER GASTROINTESTINAL

PID2020-115097RA-I00

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal de I+D+i Orientado a los Retos de la Sociedad
Convocatoria Proyectos de I+D+i (Generación de Conocimiento y Retos Investigación)
Año convocatoria 2020
Plan Estatal 2017-2020 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario FUNDACIO PRIVADA INSTITUT D'INVESTIGACIO ONCOLOGICA DE VALL-HEBRON (VHIO)

Resultados relacionados

Resultados totales (Incluyendo duplicados): 3
Encontrada(s) 1 página(s)

Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Multimodal data integration in early-stage breast cancer

  • Llinas-Bertran, Arnau
  • Butjosa-Espín, Maria
  • Seoane Fernández, Jose Antonio
  • Barberi, Vittoria
Deep learning; Multi-omics; Multimodal data integration, Aprenentatge profund; Multiòmica; Integració de dades multimodal, Aprendizaje profundo; Multiómica; Integración de datos multimodales, The use of biomarkers in breast cancer has significantly improved patient outcomes through targeted therapies, such as hormone therapy anti-Her2 therapy and CDK4/6 or PARP inhibitors. However, existing knowledge does not fully encompass the diverse nature of breast cancer, particularly in triple-negative tumors. The integration of multi-omics and multimodal data has the potential to provide new insights into biological processes, to improve breast cancer patient stratification, enhance prognosis and response prediction, and identify new biomarkers. This review presents a comprehensive overview of the state-of-the-art multimodal (including molecular and image) data integration algorithms developed and with applicability to breast cancer stratification, prognosis, or biomarker identification. We examined the primary challenges and opportunities of these multimodal data integration algorithms, including their advantages, limitations, and critical considerations for future research. We aimed to describe models that are not only academically and preclinically relevant, but also applicable to clinical settings., This work was supported by Spanish Ministry of Science, Innovation and Universities [FPU22/03520] (to MB), Programa Talentos Fundació Catalunya La Pedrera (to VB), AEI grants, including the Severo OchoaCenter of Excellence (FPI PRE2021-096930 (to ALB)); CMS2022-135428, RYC2019-026576-I, PID2020-115097RA-I00, FERO Breast Cancer Award, ISCIII grant (FORT23/00034); and Fundacion “la Caixa” (to JAS).
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publicación Artículo científico (JournalArticle)

Multimodal data integration in early-stage breast cancer

  • Llinas-Bertran, Arnau
  • Butjosa-Espín, Maria
  • Seoane Fernández, Jose Antonio
  • Barberi, Vittoria
Deep learning; Multi-omics; Multimodal data integration, Aprenentatge profund; Multiòmica; Integració de dades multimodal, Aprendizaje profundo; Multiómica; Integración de datos multimodales, The use of biomarkers in breast cancer has significantly improved patient outcomes through targeted therapies, such as hormone therapy anti-Her2 therapy and CDK4/6 or PARP inhibitors. However, existing knowledge does not fully encompass the diverse nature of breast cancer, particularly in triple-negative tumors. The integration of multi-omics and multimodal data has the potential to provide new insights into biological processes, to improve breast cancer patient stratification, enhance prognosis and response prediction, and identify new biomarkers. This review presents a comprehensive overview of the state-of-the-art multimodal (including molecular and image) data integration algorithms developed and with applicability to breast cancer stratification, prognosis, or biomarker identification. We examined the primary challenges and opportunities of these multimodal data integration algorithms, including their advantages, limitations, and critical considerations for future research. We aimed to describe models that are not only academically and preclinically relevant, but also applicable to clinical settings., This work was supported by Spanish Ministry of Science, Innovation and Universities [FPU22/03520] (to MB), Programa Talentos Fundació Catalunya La Pedrera (to VB), AEI grants, including the Severo OchoaCenter of Excellence (FPI PRE2021-096930 (to ALB)); CMS2022-135428, RYC2019-026576-I, PID2020-115097RA-I00, FERO Breast Cancer Award, ISCIII grant (FORT23/00034); and Fundacion “la Caixa” (to JAS).
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publicación Artículo científico (JournalArticle)

Epigenetic fingerprints link early-onset colon and rectal cancer to pesticide exposure

  • Maas, Silvana C.E.
  • Lemler, Lea
  • Butjosa, Maria
  • Blanco Irazuegui, Odei
  • Seoane, Jose A.
  • Baraibar, Iosune
  • Tabernero, Josep
  • Elez, Elena
Epigenetic fingerprints; Colon and rectal cancer; Pesticide exposure, Empremtes digitals epigenètiques; Càncer de còlon i recte; Exposició a pesticides, Huellas digitales epigenéticas; Cáncer de colon y recto; Exposición a pesticidas, The incidence of colorectal cancer (CRC) is rising rapidly in people younger than 50 years. Although this increase parallels shifts in lifestyle and environmental factors—collectively termed the exposome—whether these are indeed linked to the development of early-onset CRC (EOCRC) remains uninvestigated. Due to limited exposome data in most cancer cohorts, we constructed weighted methylation risk scores as proxies for exposome exposure to pinpoint specific risk factors associated with EOCRC compared to late-onset CRC (LOCRC) patients diagnosed at ≥70 years. Our analysis confirmed previously identified risk factors, including educational attainment, diet and smoking habits. Moreover, we identified exposure to the herbicide picloram as a new risk factor (adjusted P = 4.4 × 10−4) in the discovery cohort (31 EOCRC versus 100 LOCRC), which was replicated in a meta-analysis comprising nine CRC cohorts (P = 3.1 × 10−3; adjusted P = 1.5 × 10−2; 83 EOCRC versus 272 LOCRC). Subsequently, we analyzed population-based data from 94 US counties over 21 years and validated the association between picloram use and EOCRC incidence (P = 4.52 × 10−4), which remained significant after adjusting for socioeconomic factors and other pesticide use. These findings highlight the critical role of the exposome in EOCRC risk, underscoring the urgency for targeted personal and policy-level interventions., First and foremost, we thank the participants and their families who took part in the studies analyzed. We are grateful to the investigators and data management teams who recruited the participants and to the pathologists who collected the samples. We thank J. Carmona and members of the Cancer Computational Biology Group for the helpful discussions. The results shown here are based, in part, on data generated by the TCGA Research Network (https://www.cancer.gov/tcga) and the SEER Program (www.seer.cancer.gov) SEER*Stat Database: Incidence—SEER Plus Research Data, 8 Registries, November 2021 submission (1975–2019)—Linked To County Attributes based on the November 2021 submission. This research was funded by the Instituto de Salud Carlos III (FORT23/00034), cofinanced by the European Regional Development Fund/European Social Fund ‘A way to make Europe’/‘Investing in your future.’ Grants CMS2022-135428, RYC2019-026576-I (to J.A.S.), JDC2022-048829-I (to S.C.E.M.) and FPU22/03520 (to M.B.E.) funded by MICIU/AEI/10.13039/501100011033 and, as appropriate, by ‘ESF Investing in your future,’ by ESF+ or by European Union NextGenerationEU/PRTR. Grant PID2020-115097RA-I00 funded by MICIU/AEI/ 10.13039/501100011033 (to J.A.S.) and, as appropriate, by ‘ERDF A way of making Europe,’ by ERDF/EU, by the European Union or by the European Union NextGenerationEU/PRTR and Ayuda Postdoctoral AECC POSTD258824MAAS (to S.C.E.M.). The research leading to these results has received funding from la Caixa Foundation. This work was supported by the VHIO-CRIS Program for Precision Oncology and Digitalization from Fundación CRIS Contra el Cáncer. VHIO would like to acknowledge the State Agency for Research (Agencia Estatal de Investigación) for the financial support as a Center of Excellence Severo Ochoa (CEX2020-001024-S/AEI/10.13039/501100011033), the Cellex Foundation for providing research facilities and equipment and the CERCA Program from the Generalitat de Catalunya for their support on this research. The funders had no role in study design, data collection and analysis, decision to publish or preparation of the manuscript.